Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 15/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 15/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2704377 | 0.86 | DPP4 (0.67) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2705111 | 0.84 | DPP4 (0.51) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2704440 | 0.84 | DPP4 (0.56) | DPP4DPP8DPP9CYP3A4 | |
| SCHEMBL4403863 | 0.82 | DPP4 (0.60) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL4410390 | 0.81 | DPP4 (0.61) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2704347 | 0.80 | DPP4 (0.74) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2703609 | 0.79 | PLA2G2A (0.42) | DPP4DPP8DPP9CYP3A4PLA2G2A | |
| SCHEMBL8268877 | 0.77 | DPP4 (0.55) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL13870395 | 0.75 | DPP4 (0.55) | DPP4DPP8DPP9CYP3A4CYP2C19 | |
| SCHEMBL2703277 | 0.75 | DPP4 (0.63) | DPP4DPP8DPP9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 7/4885DPP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.